The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta‐analysis. (8th July 2021)

• Record Type: Journal Article
• Authors: Schumacher, Pia M.; Becker, Nicolas; Tsuyuki, Ross T.; Griese‐Mammen, Nina; Koshman, Sheri L.; McDonald, Michael A.; Bouvy, Marcel; Rutten, Frans H.; Laufs, Ulrich; Böhm, Michael; Schulz, Martin
• Is Part Of: ESC heart failure. Volume 8:Number 5(2021)
• Page Start: 3566
• Page End: 3576
• Publication Date: 2021-07-08
• Subjects: Heart failure -- Outpatients -- Pharmacist care -- Systematic review -- Meta‐analysis; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.13508
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Aims: Patients with heart failure (HF) have poor outcomes, including poor quality of life, and high morbidity and mortality. In addition, they have a high medication burden due to the multiple drug therapies now recommended by guidelines. Previous reviews, including studies in hospital settings, provided evidence that pharmacist care improves outcomes in patients with HF. Because most HF is managed outside of hospitals, we aimed to synthesize the evidence for pharmacist care in outpatients with HF. Methods and results: We conducted a systematic literature search in PubMed of randomized controlled trials (RCTs) and integrated the evidence on patient outcomes in a meta‐analysis. We found 24 RCTs performed in 10 countries, including 8029 patients. The data revealed consistent improvements in medication adherence (independent of the measuring instrument) and knowledge, physical function, and disease and medication management. Sixteen RCTs were included in meta‐analyses. Differences in all‐cause mortality (odds ratio (OR) = 0.97 [95% CI, 0.84–1.12], Q ‐statistic, P = 0.49, I 2 = 0%), all‐cause hospitalizations (OR = 0.86 [0.73–1.03], Q ‐statistic, P = 0.01, I 2 = 45.5%), and HF hospitalizations (OR = 0.89 [0.77–1.02], Q ‐statistic, P = 0.11, I 2 = 0%) were not statistically significant. We also observed an improvement in the standardized mean difference for generic quality of life of 0.75 ([0.49–1.01], P < 0.01), with no indication of heterogeneity ( Q ‐statistic, P = 0.64; I 2 = 0%). Conclusions: Results indicate that pharmacist care improves medication adherence and knowledge, symptom control, and some measures of quality of life in outpatients with HF. Given the increasing complexity of guideline‐directed medical therapy, pharmacists' unique focus on medication management, titration, adherence, and patient teaching should be considered part of the management strategy for these vulnerable patients.